Sagimet Biosciences to host KOL event on denifanstat results

Sagimet Biosciences (SGMT) will host a virtual key opinion leader event on Monday, June 16, 2025 at 2:00 PM ET. The event will feature key opinion leaderNeal Bhatia, who will join company management to review positive efficacy and tolerability results from a Phase 3 clinical trial evaluating denifanstat for the treatment of moderate to severe acne vulgaris in China conducted by Sagimet’s license partner Ascletis. Denifanstat is a once-daily oral small molecule fatty acid synthase inhibitor. In the Phase 3 study, denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated. The robust Phase 3 results underline the potential of FASN inhibition as a novel mechanism of action to address acne, a condition that impacts more than 50 million people in the U.S. annually. Management will also discuss the Company’s recently initiated Phase 1 first in-human study with its second oral FASN inhibitor drug candidate, TVB-3567, which is planned to be developed for acne in the U.S.